{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Pathologic complete response was achieved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Pathologic complete response was not achieved"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The pCRR was assessed via surgical pathology report. Pathologic complete response will require no viable cancer cells on the surgical pathology report after neoadjuvant treatment with carboplatin, nab-paclitaxel, and durvalumab. This study protocol requires the same neoadjuvant therapy and surgery for all subjects. The primary outcome measure is the complete pathologic response defined by the surgical pathology report and is unrelated to adjuvant therapy.","groups":[{"description":"All subjects received neoadjuvant chemotherapy and underwent surgery, and histopathological analyses were completed.","id":"OG000","title":"Pathologic Complete Response"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subjects received treatment in 4 cancer centers in the United States.","reportingStatus":"POSTED","timeFrame":"After surgery (approximately 8-12 weeks after start of study treatment)","title":"Pathologic Complete Response Rate (pCRR) After Induction Chemotherapy With Carboplatin, Nab-paclitaxel, and Durvalumab in Previously Untreated Stage III and IV SCCHN Amenable to Surgical Resection","type":"PRIMARY","unitOfMeasure":"Participants"}